Jeryl L. Hilleman has served as a member of our Board of Directors since December 2019, and she is the chairperson of our Audit Committee. Ms. Hilleman brings extensive experience in life sciences and served as a public company CFO for close to 20 years. Most recently, from June 2014 to November 2019, Ms. Hilleman served as the Chief Financial Officer for Intersect ENT, Inc., a commercial medical device company. Prior to Intersect ENT, Ms. Hilleman served as Chief Financial Officer of several other public healthcare companies. Ms. Hilleman has served as a member of the board of directors and the chair of the Audit Committee of NovoCure, Limited since July 2018 and as a director and chair of the board of Omada Health, Inc. since July 2018. Ms. Hilleman previously served as a member of the board of directors of HilleVax, Inc. From July 2021 to September 2025, Cutera, Inc. from July 2024 to February 2025, Minerva Neurosciences, Inc. from July 2018 to August 2024, Talis Biomedical Corporation from February 2021 to June 2022, and Xenoport, Inc. from January 2005 to July 2016. Ms. Hilleman received a B.A. in History from Brown University and an M.B.A. from the Wharton School at the University of Pennsylvania. We believe Ms. Hilleman s financial experience, experience with medical device companies, and her knowledge of our company enable her to make valuable contributions to our Board of Directors.